Your browser doesn't support javascript.
loading
Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib.
Manda, Sudhir; Yimer, Habte A; Noga, Stephen J; Girnius, Saulius; Yasenchak, Christopher A; Charu, Veena; Lyons, Roger; Aiello, Jack; Bogard, Kimberly; Ferrari, Renda H; Cherepanov, Dasha; Demers, Brittany; Lu, Vickie; Whidden, Presley; Kambhampati, Suman; Birhiray, Ruemu E; Jhangiani, Haresh S; Boccia, Ralph; Rifkin, Robert M.
Afiliación
  • Manda S; Arizona Oncology/US Oncology Research, Tucson, AZ.
  • Yimer HA; Texas Oncology/US Oncology Research, Tyler, TX.
  • Noga SJ; Millennium Pharmaceuticals, Inc, Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Tokyo, Japan.
  • Girnius S; Trihealth Cancer Institute, Cincinnati, OH.
  • Yasenchak CA; Willamette Valley Cancer Institute and Research Center/US Oncology Research, Eugene, OR.
  • Charu V; Pacific Cancer Medical Center, Anaheim, CA.
  • Lyons R; Texas Oncology/US Oncology Research, San Antonio, TX.
  • Aiello J; Patient Empowerment Network, San Jose, CA.
  • Bogard K; Millennium Pharmaceuticals, Inc, Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Tokyo, Japan.
  • Ferrari RH; Millennium Pharmaceuticals, Inc, Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Tokyo, Japan.
  • Cherepanov D; Millennium Pharmaceuticals, Inc, Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Tokyo, Japan.
  • Demers B; Millennium Pharmaceuticals, Inc, Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Tokyo, Japan.
  • Lu V; Millennium Pharmaceuticals, Inc, Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Tokyo, Japan.
  • Whidden P; Millennium Pharmaceuticals, Inc, Cambridge, MA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Tokyo, Japan.
  • Kambhampati S; Kansas City Veterans Affairs Medical Center, Kansas City, MO.
  • Birhiray RE; Hematology Oncology of Indiana/American Oncology Network, Indianapolis, IN.
  • Jhangiani HS; Compassionate Cancer Care Medical Group, Fountain Valley, CA.
  • Boccia R; Center for Cancer and Blood Disorders, Bethesda, MD.
  • Rifkin RM; Rocky Mountain Cancer Centers/US Oncology Research, Denver, CO. Electronic address: robert.rifkin@usoncology.com.
Clin Lymphoma Myeloma Leuk ; 20(11): e910-e925, 2020 11.
Article en En | MEDLINE | ID: mdl-32912820
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Compuestos de Boro / Protocolos de Quimioterapia Combinada Antineoplásica / Inhibidores de Proteasoma / Bortezomib / Glicina / Mieloma Múltiple Límite: Aged / Female / Humans / Male Idioma: En Revista: Clin Lymphoma Myeloma Leuk Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: Azerbaiyán
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Compuestos de Boro / Protocolos de Quimioterapia Combinada Antineoplásica / Inhibidores de Proteasoma / Bortezomib / Glicina / Mieloma Múltiple Límite: Aged / Female / Humans / Male Idioma: En Revista: Clin Lymphoma Myeloma Leuk Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: Azerbaiyán